Skip to main content
. 2016 Mar 3;95(8):e2697. doi: 10.1097/MD.0000000000002697

FIGURE 1.

FIGURE 1

PD-0332991 selectively inhibited proliferation of TP53 mutant cells. A, Glioblastoma TP366 and LN229 cells were treated with different concentrations of PD-033991 for 3 days followed by MTT assay. B, Glioblastoma TP366 and LN229 cells were treated with 5 μM PD-033991 for indicated time points followed by CCK8 assay. C, Hepatocellular carcinoma HepG2, Hep3B, and Huh7 cells were treated with indicated concentrations of PD-033991 for 3 days followed by MTT assay. D, Hepatocellular carcinoma HepG2, Hep3B, and Huh7 cells were treated with 5 μM PD-033991 for indicated time points followed by CCK8 assay. Data were expressed as mean ± S.E. ∗, P < 0.05; ∗∗, P < 0.01 (n = 4 or 6, the experiments were repeated at least twice).